A novel IFNα-induced long noncoding RNA negatively regulates immunosuppression by interrupting H3K27 acetylation in head and neck squamous cell carcinoma
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A novel IFNα-induced long noncoding RNA negatively regulates immunosuppression by interrupting H3K27 acetylation in head and neck squamous cell carcinoma
Authors
Keywords
-
Journal
Molecular Cancer
Volume 19, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-02-03
DOI
10.1186/s12943-019-1123-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- p53-targeted lincRNA-p21 acts as a tumor suppressor by inhibiting JAK2/STAT3 signaling pathways in head and neck squamous cell carcinoma
- (2019) Shufang Jin et al. Molecular Cancer
- Severe immune related adverse events are common with sequential PD-(L)1 blockade and osimertinib
- (2019) A J Schoenfeld et al. ANNALS OF ONCOLOGY
- The long noncoding RNA Lnczc3h7a promotes a TRIM25-mediated RIG-I antiviral innate immune response
- (2019) Hongyu Lin et al. NATURE IMMUNOLOGY
- Interferon-inducible cytoplasmic lncLrrc55-AS promotes antiviral innate responses by strengthening IRF3 phosphorylation
- (2019) Yumei Zhou et al. CELL RESEARCH
- Blockade of TGF-β signaling to enhance the antitumor response is accompanied by dysregulation of the functional activity of CD4+CD25+Foxp3+ and CD4+CD25−Foxp3+ T cells
- (2019) Magdalena J. Polanczyk et al. Journal of Translational Medicine
- Identification of Renal Long Non-coding RNA RP11-2B6.2 as a Positive Regulator of Type I Interferon Signaling Pathway in Lupus Nephritis
- (2019) Zhuojun Liao et al. Frontiers in Immunology
- Tumor-induced peripheral immunosuppression promotes brain metastasis in patients with non-small cell lung cancer
- (2019) Yuping D. Li et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Interferon-inducible lncRNA IRF1-AS represses esophageal squamous cell carcinoma by promoting interferon response
- (2019) Jianbing Huang et al. CANCER LETTERS
- The Dark Side of Fibroblasts: Cancer-Associated Fibroblasts as Mediators of Immunosuppression in the Tumor Microenvironment
- (2019) Lea Monteran et al. Frontiers in Immunology
- Prim-O-glucosylcimifugin enhances the antitumour effect of PD-1 inhibition by targeting myeloid-derived suppressor cells
- (2019) Wanfeng Gao et al. Journal for ImmunoTherapy of Cancer
- Interferon-alpha enhances the antitumour activity of EGFR-targeted therapies by upregulating RIG-I in head and neck squamous cell carcinoma
- (2018) Hailong Ma et al. BRITISH JOURNAL OF CANCER
- Cancer statistics, 2018
- (2018) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Self-Recognition of an Inducible Host lncRNA by RIG-I Feedback Restricts Innate Immune Response
- (2018) Minghong Jiang et al. CELL
- Long noncoding RNA BLACAT2 promotes bladder cancer–associated lymphangiogenesis and lymphatic metastasis
- (2018) Wang He et al. JOURNAL OF CLINICAL INVESTIGATION
- Loss of GAS5 tumour suppressor lncRNA: an independent molecular cancer biomarker for short-term relapse and progression in bladder cancer patients
- (2018) Margaritis Avgeris et al. BRITISH JOURNAL OF CANCER
- Interferon-alpha promotes immunosuppression through IFNAR1/STAT1 signalling in head and neck squamous cell carcinoma
- (2018) Hailong Ma et al. BRITISH JOURNAL OF CANCER
- H19 regulation of oestrogen induction of symmetric division is achieved by antagonizing Let-7c in breast cancer stem-like cells
- (2018) Meng Wang et al. CELL PROLIFERATION
- LncRNA MIR31HG targets HIF1A and P21 to facilitate head and neck cancer cell proliferation and tumorigenesis by promoting cell-cycle progression
- (2018) Ru Wang et al. Molecular Cancer
- Stathmin is overexpressed and regulated by mutant p53 in oral squamous cell carcinoma
- (2017) Hai-long Ma et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Autocrine activation of the IFN signaling pathway may promote immune escape in glioblastoma
- (2017) Manuela Silginer et al. NEURO-ONCOLOGY
- Tumor Mutational Burden and Response Rate to PD-1 Inhibition
- (2017) Mark Yarchoan et al. NEW ENGLAND JOURNAL OF MEDICINE
- An interferon-independent lncRNA promotes viral replication by modulating cellular metabolism
- (2017) Pin Wang et al. SCIENCE
- Interferon-α Promotes the Expression of Cancer Stem Cell Markers in Oral Squamous Cell Carcinoma
- (2017) Hailong Ma et al. Journal of Cancer
- Alpha and Beta Type 1 Interferon Signaling: Passage for Diverse Biologic Outcomes
- (2016) Cherie T. Ng et al. CELL
- Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy
- (2016) Lucie Heinzerling et al. Journal for ImmunoTherapy of Cancer
- The Galectin-9/Tim-3 pathway is involved in the regulation of NK cell function at the maternal–fetal interface in early pregnancy
- (2015) Yan-Hong Li et al. Cellular & Molecular Immunology
- Long noncoding RNA derived from CD244 signaling epigenetically controls CD8+T-cell immune responses in tuberculosis infection
- (2015) Yang Wang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade
- (2015) D. M. Woods et al. Cancer Immunology Research
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- The Noncoding RNA MALAT1 Is a Critical Regulator of the Metastasis Phenotype of Lung Cancer Cells
- (2012) T. Gutschner et al. CANCER RESEARCH
- Low dosed interferon alpha augments the anti-tumor potential of histone deacetylase inhibition on prostate cancer cell growth and invasion
- (2012) Lukasz Hudak et al. PROSTATE
- Macrophage Diversity Enhances Tumor Progression and Metastasis
- (2010) Bin-Zhi Qian et al. CELL
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More